FDA Advisory Panel Recommends Approval of Chelsea Therapeutics' NORTHERA(TM) (Droxidopa) for the Treatment of Symptomatic nOH
January 14, 2014 17:09 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs...
Chelsea Therapeutics Announces First Patient Dosed in NORTHERA(TM) (droxidopa) Study 401 for the Treatment of Symptomatic nOH
December 09, 2013 07:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that the first patient has been dosed in Study 401, a multi-center,...
Chelsea Therapeutics Completes Public Offering of Common Stock
November 18, 2013 10:32 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), a development stage pharmaceutical company focused on the acquisition, development and...
Chelsea Therapeutics Announces Pricing of Public Offering of Common Stock
November 13, 2013 08:44 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 13, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), a development stage pharmaceutical company focused on the acquisition, development and...
Chelsea Therapeutics Announces Public Offering of Common Stock
November 12, 2013 17:49 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), a development stage pharmaceutical company focused on the acquisition, development and...
Chelsea Therapeutics Reports Third Quarter 2013 Financial Results
November 05, 2013 16:22 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the third quarter ended September 30, 2013.
"The third...
Chelsea Therapeutics Announces FDA Advisory Committee to Review NORTHERA(TM) (droxidopa)
October 09, 2013 16:01 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Oct. 9, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that...
Chelsea Therapeutics to Present at BioCentury's 2013 Newsmakers in the Biotech Industry Conference
September 19, 2013 07:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at BioCentury's 2013 Newsmakers in the Biotech Industry Conference at...
Chelsea Therapeutics Announces FDA Acceptance of NORTHERA(TM) (droxidopa) NDA Resubmission
September 04, 2013 16:01 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of...
Chelsea Therapeutics Announces Submission of Additional Information for NORTHERA(TM) (Droxidopa) NDA
August 14, 2013 07:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that it has submitted additional information to the U.S. Food and Drug...